HLA-A: Major Histocompatibility Complex Class I Heavy Chain, Antigen Presentation, and CD8+ T-Cell Recognition

By Dr. Zubair Khalid, DVM, MS, PhD · 2026-08-01

Key Takeaways

• HLA-A, a major histocompatibility complex class I heavy chain, presents endogenously derived peptides (8-10 amino acids) to CD8+ cytotoxic T lymphocytes (CTLs) via its polymorphic peptide-binding groove, crucial for immune surveillance against intracellular pathogens and neoplastic transformation.
• The extraordinary allelic diversity of HLA-A (over 7,500 alleles) is concentrated in exons encoding the peptide-binding domains (exons 2 and 3), reflecting balancing selection and underpinning population-level resilience against pathogen evasion, but also contributing to alloreactivity in transplantation and disease susceptibility.
• HLA-A expression is tightly regulated by promoter elements (SXY module, ISRE, NF-κB sites) and is upregulated by interferons and pro-inflammatory cytokines, while its presentation pathway involves proteasomal degradation, TAP transport into the ER, and loading onto the heavy chain within the peptide-loading complex.
• Viral pathogens employ sophisticated evasion strategies, such as HIV-1 Nef and HCMV US2/US3/US6/US11, to downregulate HLA-A surface expression or inhibit its antigen presentation pathway, thereby escaping CTL recognition.
• Specific HLA-A alleles are established pharmacogenomic biomarkers for severe drug hypersensitivity reactions, notably HLA-A*31:01 with carbamazepine-induced Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) and HLA-A*32:01 with vancomycin-induced DRESS.
• Therapeutic strategies, including immune checkpoint inhibitors and TCR-engineered T-cell therapies, rely on HLA-A-mediated presentation of tumor-associated antigens; conversely, loss-of-function mutations in HLA-A or B2M are associated with resistance to these immunotherapies.

Executive Summary & Key Metadata

The HLA-A gene encodes the heavy chain (alpha chain) of the human leukocyte antigen (HLA) class I molecule, a polymorphic transmembrane glycoprotein central to adaptive immunity. HLA-A presents endogenously derived peptide antigens (8–10 amino acids) to CD8+ cytotoxic T lymphocytes (CTLs), thereby enabling immune surveillance against intracellular pathogens and neoplastic transformation. The extraordinary allelic diversity of HLA-A (with over 7,000 known alleles) confers population-level resilience against pathogen evasion but also underpins alloreactivity in transplantation and associations with autoimmune and infectious disease susceptibility.

The HLA-A molecule functions as a trimeric complex comprising the polymorphic heavy chain (encoded by HLA-A), the invariant β2-microglobulin (β2m, encoded by B2M on chromosome 15), and a bound peptide antigen. The heavy chain is organized into three extracellular domains (α1, α2, α3), a transmembrane segment, and a short cytoplasmic tail. The α1 and α2 domains fold to form the peptide-binding groove, a platform of eight antiparallel β-strands topped by two α-helices. This groove accommodates peptides anchored at defined positions (P2 and P9 for HLA-A*02:01), a feature exploited in epitope prediction algorithms and vaccine design [1, 2].

1. Genomic Locus, Chromosomal Organization & Isoforms

1.1 Chromosomal Localization and Genomic Architecture

HLA-A resides within the major histocompatibility complex (MHC) class I region on the short arm of chromosome 6 at cytogenetic band 6p21.33. The MHC spans approximately 3.6 megabases and is subdivided into three regions: class I (telomeric), class III (central), and class II (centromeric). The class I region contains the classical transplantation antigens HLA-A, HLA-B, and HLA-C, as well as non-classical genes HLA-E, HLA-F, and HLA-G [<a href="#ref-3">3</a>]. The genomic coordinates for HLA-A (GRCh38/hg38) are approximately chr6:29,942,066–29,945,885 (plus strand), encompassing roughly 3.8 kilobases of genomic DNA. The gene comprises 8 exons and 7 introns, with the coding sequence distributed across exons 1–5 and 8, while exons 6 and 7 are partially translated.

The HLA-A gene structure is as follows:

• Exon 1: Encodes the leader peptide (signal sequence) of 24 amino acids, which directs the nascent polypeptide into the endoplasmic reticulum (ER) lumen.
• Exon 2: Encodes the α1 domain (amino acids 25–114 of the mature protein), contributing half of the peptide-binding groove.
• Exon 3: Encodes the α2 domain (amino acids 115–206), completing the peptide-binding groove.
• Exon 4: Encodes the α3 domain (amino acids 207–297), an immunoglobulin-like constant domain that binds CD8.
• Exon 5: Encodes the transmembrane region (amino acids 298–323), a hydrophobic α-helix anchoring the molecule to the plasma membrane.
• Exons 6 and 7: Encode the cytoplasmic tail (amino acids 324–365), containing phosphorylation sites and endocytosis motifs.
• Exon 8: Contains the 3' untranslated region (UTR) and polyadenylation signal.

1.2 Promoter Architecture and Transcriptional Regulation

The HLA-A promoter is a TATA-less, initiator (Inr)-driven promoter located approximately 200 base pairs upstream of the transcription start site (TSS). Key regulatory elements include:

• SXY module: A conserved regulatory module (S, X1, X2, and Y boxes) located between −200 and −50 bp upstream of the TSS. The X1 box binds regulatory factor X (RFX) complex, the X2 box binds cAMP-responsive element-binding protein (CREB)/activating transcription factor (ATF), and the Y box binds nuclear transcription factor Y (NF-Y). Together, these elements form an enhanceosome that recruits the class II transactivator (CIITA) in a cell-type-specific manner, although CIITA primarily regulates class II genes, it also modulates class I expression in some contexts.
• Interferon-stimulated response element (ISRE): Located upstream of the SXY module, this element binds interferon regulatory factors (IRF1, IRF2) and signal transducer and activator of transcription 1 (STAT1) in response to type I and type II interferons (IFN-α/β and IFN-γ), driving robust transcriptional upregulation during inflammation.
• NF-κB binding sites: Nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) binds to cognate motifs in the promoter, linking HLA-A expression to pro-inflammatory cytokine signaling (e.g., tumor necrosis factor-alpha, TNF-α).
• Enhancer elements: A distal enhancer region located approximately 1 kb upstream contains binding sites for the transcription factors SP1 and AP-1, contributing to basal transcriptional activity.

1.3 Allelic Diversity and Haplotype Structure

HLA-A is among the most polymorphic genes in the human genome, with the IPD-IMGT/HLA database (release 3.52.0) cataloging over 7,500 alleles. Polymorphisms are concentrated in exons 2 and 3, which encode the peptide-binding domains, reflecting balancing selection driven by pathogen diversity. Alleles are named according to the WHO HLA Nomenclature Committee system, with four-digit resolution indicating distinct protein products (e.g., HLA-A*02:01) and six-to-eight-digit resolution distinguishing synonymous or non-coding variants.

Population-specific allele distributions have been documented extensively. For example, HLA-A*02:01 is the most common allele in Caucasian populations (allele frequency ~27%), whereas HLA-A*11:01 predominates in East Asian populations (allele frequency ~30%). A study of the Punjab population in Pakistan reported HLA-A*02 as the most frequent allele (22.2%), followed by HLA-A*11 (13.4%) and HLA-A*24 (11.1%) [<a href="#ref-4">4</a>]. Such population-specific distributions have implications for transplant matching and epitope-based vaccine design.

1.4 Alternative Splicing and Isoforms

Alternative splicing of HLA-A generates multiple mRNA isoforms, although the functional significance of most remains incompletely characterized. The primary transcript undergoes canonical splicing to yield the full-length membrane-bound heavy chain. Additionally, the following isoforms have been described:

• Soluble HLA-A (sHLA-A): Generated by alternative splicing that skips exon 5 (transmembrane domain), producing a secreted form lacking the membrane anchor. sHLA-A is detectable in serum and plasma, with elevated levels observed in inflammatory conditions, transplantation rejection, and certain malignancies. The functional role of sHLA-A includes immune modulation, potentially inducing apoptosis in activated CD8+ T cells via Fas/FasL interactions.
• Truncated isoforms: Splicing variants that retain intronic sequences or skip exons 6–7 produce C-terminally truncated heavy chains. These isoforms may be retained in the ER or targeted for proteasomal degradation, potentially serving as a source of HLA-A-derived peptides presented by other class I molecules.
• N-terminally extended isoforms: Rare splice variants utilizing alternative upstream TSSs or retaining exon 1-derived sequences produce leader-extended proteins, whose functional relevance is unclear.

2. 3D Protein Domain Architecture & Structural Biology

2.1 Overall Fold and Domain Organization

The HLA-A heavy chain (UniProt P01892) is a type I transmembrane glycoprotein of 365 amino acids (mature protein: 341 amino acids after signal peptide cleavage). The three-dimensional structure, first solved by X-ray crystallography for HLA-A*02:01 complexed with an influenza matrix peptide (PDB: 1HHK), reveals a modular architecture:

• α1 domain (residues 1–90 of mature protein): Comprises a four-stranded antiparallel β-sheet (β1–β4) followed by a long α-helix (α1 helix). The β-sheet forms the floor of the peptide-binding groove, while the α1 helix forms one wall.
• α2 domain (residues 91–182): Adopts a similar topology to α1, with a four-stranded β-sheet and an α2 helix. The α2 helix forms the opposite wall of the peptide-binding groove. The α1 and α2 helices together create a closed groove approximately 30 Å long, 12 Å wide, and 8 Å deep, accommodating peptides of 8–10 residues.
• α3 domain (residues 183–274): An immunoglobulin-like constant domain with a β-sandwich fold (two antiparallel β-sheets). This domain contains the CD8 binding loop (residues 223–229), which interacts with the CD8α chain on T cells, stabilizing the TCR–pMHC interaction.
• Transmembrane domain (residues 275–297): A hydrophobic α-helix spanning the lipid bilayer, anchoring the heavy chain to the cell surface.
• Cytoplasmic tail (residues 298–341): Contains phosphorylation sites (Ser335, Ser338) and a di-leucine motif (Leu339-Leu340) involved in endocytosis and intracellular trafficking.

2.2 Peptide-Binding Groove Architecture

The peptide-binding groove is the defining structural feature of HLA-A. It is composed of six binding pockets (A–F) that accommodate peptide side chains:

• Pocket A: Located at the N-terminus of the groove, binds the free amino group of the peptide (P1). Highly conserved across class I molecules.
• Pocket B: Binds the P2 anchor residue. For HLA-A*02:01, this pocket is hydrophobic, preferring leucine or methionine. Polymorphic residues at positions 7, 9, 24, 34, 45, 63, 66, 67, 70, and 99 determine pocket B specificity.
• Pocket C: Binds the P6 residue, contributing to peptide specificity.
• Pocket D: Binds the P3 residue, with moderate polymorphism.
• Pocket E: Binds the P7 residue, influencing peptide conformation.
• Pocket F: Located at the C-terminus of the groove, binds the P9 anchor residue. For HLA-A*02:01, this pocket is also hydrophobic, preferring valine or leucine. Polymorphic residues at positions 77, 80, 81, 84, 95, 97, 114, 116, 123, 133, 143, 146, and 147 determine pocket F specificity.

The peptide is bound in an extended conformation, with the N- and C-termini fixed by conserved hydrogen-bond networks involving tyrosine residues (Tyr7, Tyr59, Tyr84, Tyr123, Tyr159, Tyr171) and the peptide backbone. This "anchor-based" binding mode allows a single HLA-A allele to present thousands of different peptides sharing only 2–3 anchor residues, a property exploited in computational epitope prediction [1, 2].

2.3 Glycosylation and Post-Translational Modifications

HLA-A heavy chain is N-glycosylated at Asn86 (within the α1 domain), with a high-mannose glycan added co-translationally in the ER. This glycan is processed to a complex-type oligosaccharide in the Golgi apparatus before cell-surface expression. Glycosylation is essential for proper folding and ER exit; inhibition of N-linked glycosylation (e.g., by tunicamycin) results in ER retention and degradation of the heavy chain.

Additional post-translational modifications include:

• Phosphorylation: Serine residues in the cytoplasmic tail (Ser335, Ser338) are phosphorylated by protein kinase C (PKC) and casein kinase II (CK2), modulating endocytosis and intracellular trafficking.
• Palmitoylation: Cys337 in the cytoplasmic tail can be palmitoylated, anchoring the tail to the inner leaflet of the plasma membrane and influencing membrane microdomain localization.
• Ubiquitination: Lysine residues in the cytoplasmic tail can be ubiquitinated, targeting the molecule for endosomal degradation, a mechanism exploited by viral immune evasion proteins (e.g., HIV-1 Nef).

2.4 Structural Comparison with Other Class I Molecules

HLA-A shares ~85% sequence identity with HLA-B and ~80% with HLA-C in the α1–α3 domains. The overall fold is conserved, but key differences exist in the peptide-binding groove:

• HLA-B: Generally has a more hydrophobic pocket B, preferring proline or alanine at P2.
• HLA-C: Has a narrower groove due to a tryptophan at position 97, restricting peptide length to 8–9 residues. HLA-C also serves as a ligand for killer-cell immunoglobulin-like receptors (KIRs), a function not shared by HLA-A.

2.5 Interactive 3D Visualization

Interactive 3D Protein Visualizer: Load HLA-A (PDB: 1HHK)

The interactive visualizer allows exploration of the HLA-A*02:01 structure in atomic detail. Users can:

• Rotate and zoom the trimeric complex (heavy chain, β2m, peptide).
• Color domains by secondary structure (α1: red, α2: blue, α3: green, β2m: yellow, peptide: magenta).
• Display the peptide-binding groove surface with electrostatic potential.
• Highlight anchor residues (P2 and P9) and CD8 binding loop.
• Superimpose allelic variants (e.g., HLA-A*11:01, PDB: 1X7Q) to visualize polymorphic differences.

3. Cellular Signaling Pathways & Molecular Function

3.1 Antigen Processing and Loading Pathway

The HLA-A antigen presentation pathway is a multi-step process that ensures the display of intracellular protein fragments at the cell surface. The pathway can be summarized as follows:

1. Proteasomal degradation: Cytosolic proteins are ubiquitinated and degraded by the 26S proteasome, generating peptide fragments of 8–16 amino acids. The immunoproteasome, induced by IFN-γ, contains alternative catalytic subunits (β1i/LMP2, β2i/MECL-1, β5i/LMP7) that enhance cleavage after hydrophobic and basic residues, favoring MHC class I binding.
2. Peptide transport: Peptides are translocated into the ER lumen by the transporter associated with antigen processing (TAP), a heterodimeric ABC transporter (TAP1/TAP2). TAP preferentially transports peptides of 8–16 residues with hydrophobic or basic C-termini.
3. Peptide loading complex (PLC): In the ER, the PLC assembles, comprising TAP, tapasin, calreticulin, ERp57, and the chaperone BiP. Tapasin stabilizes the empty HLA-A heavy chain–β2m dimer, facilitates peptide editing (selection of high-affinity peptides), and retains the complex in the ER until a suitable peptide is bound.
4. Peptide editing and quality control: Tapasin and ERp57 mediate peptide exchange, favoring peptides with slow off-rates (high affinity). The final peptide–MHC class I (pMHC) complex is released from the PLC and exported to the Golgi via COPII-coated vesicles.
5. Cell-surface expression: The mature pMHC complex is transported to the plasma membrane, where it presents the peptide to CD8+ T cells.

sequenceDiagram
    participant R as "Ribosome"
    participant C as "Cytosolic Protein"
    participant P as "Proteasome"
    participant T as "TAP"
    participant E as "ER Lumen"
    participant L as "PLC (Tapasin/Calreticulin/ERp57)"
    participant H as "HLA-A Heavy Chain + β2m"
    participant G as "Golgi"
    participant M as "Plasma Membrane"
    participant Tcell as "CD8+ T Cell"
    R->>C: Translation of protein
    C->>P: Ubiquitination & degradation
    P->>T: Peptide fragments (8-16 aa)
    T->>E: ATP-dependent translocation
    E->>L: Peptide loading onto HLA-A
    L->>H: Peptide editing (tapasin)
    H->>G: COPII vesicle transport
    G->>M: Exocytosis
    M->>Tcell: pMHC presentation
    Tcell->>Tcell: TCR engagement & activation

3.2 T-Cell Receptor Engagement and Signaling

The pMHC complex on the antigen-presenting cell (APC) surface is recognized by the T-cell receptor (TCR) on CD8+ T cells. The TCR–pMHC interaction is characterized by low affinity (Kd ~1–100 μM) and fast off-rates, enabling serial engagement of multiple TCRs by a single pMHC complex. The CD8 co-receptor binds to the α3 domain of HLA-A, stabilizing the interaction and recruiting the Src kinase Lck to the TCR signaling complex.

TCR engagement triggers a signaling cascade:

1. Lck activation: CD8-bound Lck phosphorylates immunoreceptor tyrosine-based activation motifs (ITAMs) on the CD3ζ and CD3ε/γ/δ chains.
2. ZAP-70 recruitment: Syk family kinase ZAP-70 binds to phosphorylated ITAMs via its tandem SH2 domains and is activated by Lck-mediated phosphorylation.
3. Adapter protein phosphorylation: ZAP-70 phosphorylates LAT (linker for activation of T cells) and SLP-76, nucleating a signaling complex that activates phospholipase C-γ1 (PLC-γ1).
4. Calcium flux and MAPK activation: PLC-γ1 cleaves phosphatidylinositol 4,5-bisphosphate (PIP2) into inositol trisphosphate (IP3) and diacylglycerol (DAG). IP3 triggers calcium release from the ER, activating calcineurin and NFAT. DAG activates protein kinase C-θ (PKC-θ) and the Ras-MAPK pathway, leading to AP-1 activation.
5. Transcriptional activation: NFAT, AP-1, and NF-κB cooperate to induce genes encoding cytokines (IL-2, IFN-γ), cytolytic molecules (perforin, granzyme B), and survival factors, driving CTL effector function.

3.3 Cross-Presentation and CD8+ T-Cell Priming

While HLA-A presents endogenous peptides, professional APCs (dendritic cells) can also present exogenous antigens on class I molecules via cross-presentation. This process involves:

• Phagosomal pathway: Exogenous antigens are internalized into phagosomes, where they are degraded by proteases and transported into the cytosol for proteasomal processing, followed by TAP-dependent loading onto HLA-A.
• Vacuolar pathway: Antigens are degraded within endosomal compartments and loaded onto recycling HLA-A molecules.

Cross-presentation is essential for priming CD8+ T-cell responses against viruses that do not infect APCs and against tumor antigens.

3.4 NK Cell Regulation

Although HLA-A primarily interacts with TCRs, it also serves as a ligand for inhibitory receptors on natural killer (NK) cells, including:

• KIR3DL2: Binds HLA-A*03 and HLA-A*11 alleles, delivering inhibitory signals that prevent NK cell-mediated lysis of healthy cells.
• LILRB1 (ILT2): Binds HLA-A in complex with β2m, providing broad inhibitory signals.

Downregulation of HLA-A on virus-infected or tumor cells (a common immune evasion strategy) removes this inhibitory signal, rendering cells susceptible to NK cell killing ("missing-self" recognition).

3.5 Protein-Protein Interaction Networks

The HLA-A interactome includes:

• Chaperones: Calnexin, calreticulin, BiP (GRP78), ERp57 (PDIA3).
• Peptide loading complex: TAP1, TAP2, tapasin (TAPBP), and the co-chaperone BAP31.
• T-cell co-receptors: CD8α, CD8β, TCRα, TCRβ.
• NK cell receptors: KIR3DL2, LILRB1.
• Viral proteins: HIV-1 Nef, HIV-1 Vpu, CMV US2, US3, US6, US11, adenovirus E3/19K, KSHV K3/K5.

STRING analysis reveals a dense interaction network centered on TAPBP, TAP1, and B2M, with functional enrichment for antigen processing and presentation (GO:0002474).

4. Pathogenic Hotspot Mutations & Clinical Differentials

4.1 Allelic Variants and Disease Associations

The extreme polymorphism of HLA-A translates into differential disease susceptibility and clinical outcomes. Key associations include:

• **HLA-A*02:01**: Associated with reduced risk of HIV-1 progression (elite controllers) and improved responses to checkpoint inhibitor immunotherapy in melanoma. However, HLA-A*02:01 is also associated with susceptibility to type 1 diabetes in some populations.
• **HLA-A*11:01**: Associated with nasopharyngeal carcinoma (NPC) risk in Southeast Asian populations, particularly in the Minangkabau ethnic group of Indonesia [<a href="#ref-5">5</a>]. The mechanism involves presentation of Epstein-Barr virus (EBV) epitopes and potential molecular mimicry.
• **HLA-A*24:02**: Associated with Behçet's disease in Japanese populations, particularly the ocular subtype [<a href="#ref-1">1</a>]. HLA-A*26:01 shows an even stronger association with ocular Behçet's disease.
• **HLA-A*03:01**: Associated with multiple sclerosis (MS) susceptibility in Iranian populations [<a href="#ref-2">2</a>]. The allele may present myelin-derived peptides that trigger autoreactive T cells.
• **HLA-A*31:01**: Associated with carbamazepine-induced severe cutaneous adverse reactions (SCARs), including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), in East Asian populations.
• **HLA-A*32:01**: Associated with vancomycin-induced drug reaction with eosinophilia and systemic symptoms (DRESS) [<a href="#ref-3">3</a>].

4.2 Somatic Mutations in Cancer

Somatic mutations in HLA-A are common in tumors and contribute to immune evasion. These include:

• Loss-of-function mutations: Nonsense, frameshift, and splice-site mutations that abrogate heavy chain expression. Such mutations are enriched in microsatellite instability-high (MSI-H) tumors, where defective DNA mismatch repair generates insertion/deletion mutations in coding microsatellites.
• Copy number loss: Hemizygous or homozygous deletion of the HLA-A locus (6p21.3) is observed in ~15% of non-small cell lung cancers (NSCLC) and ~10% of melanomas.
• Beta-2-microglobulin (B2M) mutations: Loss-of-function mutations in B2M (chromosome 15q21.1) result in the absence of cell-surface HLA-A, as β2m is required for stable expression. B2M mutations are found in ~30% of MSI-H colorectal cancers.

These alterations are associated with resistance to immune checkpoint inhibitors (anti-PD-1/PD-L1), as tumor cells lacking HLA-A cannot present neoantigens to CD8+ T cells.

4.3 ClinVar Pathogenic Variants

ClinVar catalogs numerous HLA-A variants, though interpretation is complicated by the high degree of polymorphism. Notable classifications include:

• Pathogenic: HLA-A*31:01 (carbamazepine-induced SJS/TEN), HLA-A*32:01 (vancomycin-induced DRESS).
• Risk factor: HLA-A*11:01 (nasopharyngeal carcinoma), HLA-A*26:01 (Behçet's disease).
• Protective: HLA-A*02:01 (HIV-1 progression), HLA-A*03:01 (hepatocellular carcinoma in some populations) [<a href="#ref-4">4</a>].

4.4 Clinical Differentials and Diagnostic Considerations

The clinical evaluation of HLA-A-associated diseases requires:

• HLA typing: Sequence-based typing (SBT) or next-generation sequencing (NGS) to resolve alleles at high resolution.
• Functional assays: Peptide-binding assays, tetramer staining, and ELISpot to assess antigen presentation and T-cell responses.
• Expression analysis: Flow cytometry with pan-HLA class I antibodies (e.g., W6/32) to detect cell-surface expression [<a href="#ref-5">5</a>].

5. Host-Pathogen & Viral Interactions

5.1 Viral Immune Evasion Mechanisms

Viruses have evolved sophisticated strategies to subvert HLA-A-mediated antigen presentation:

• HIV-1 Nef: Downregulates HLA-A and HLA-B from the cell surface by binding to the cytoplasmic tail and redirecting the molecules to endolysosomal degradation. Nef does not affect HLA-C or HLA-E, preserving NK cell inhibition. This selective downregulation allows HIV-1-infected cells to evade CTL recognition while avoiding NK cell killing.
• HIV-1 Vpu: Enhances Nef-mediated downregulation and also targets newly synthesized HLA-A for ER-associated degradation (ERAD).
• Human cytomegalovirus (HCMV): Encodes multiple immune evasion proteins:
• US2: Targets HLA-A heavy chain for dislocation from the ER into the cytosol, followed by proteasomal degradation.
• US3: Retains HLA-A in the ER by binding to the heavy chain and preventing peptide loading.
• US6: Inhibits TAP, blocking peptide translocation into the ER.
• US11: Dislocates HLA-A heavy chain from the ER to the cytosol for degradation.
• Adenovirus E3/19K: Retains HLA-A in the ER by binding to the heavy chain and preventing ER exit.
• Kaposi's sarcoma-associated herpesvirus (KSHV) K3 and K5: Ubiquitinate HLA-A heavy chain, targeting it for endolysosomal degradation.

5.2 Bacterial Interactions

• Mycobacterium tuberculosis: HLA-A-restricted CD8+ T-cell responses are critical for control of M. tuberculosis infection. Specific epitopes from the Rv0350 and Rv0351 proteins (latency-associated antigens) have been identified as HLA-A*02:01-restricted CTL epitopes, providing targets for vaccine development [<a href="#ref-1">1</a>]. HLA-A*02:01 is also associated with susceptibility to tuberculosis in some populations [<a href="#ref-2">2</a>].
• Staphylococcus aureus: HLA-A allelic variation may influence susceptibility to invasive S. aureus infections, though the mechanisms remain unclear [3, 4].

5.3 Parasitic Infections

• Plasmodium falciparum: HLA-A-restricted CTL responses against liver-stage antigens (e.g., merozoite surface protein 1, MSP1) are important for malaria immunity. HLA-A*02:01-restricted epitopes have been characterized for vaccine development [<a href="#ref-5">5</a>].
• Trypanosoma brucei: Host genetic factors, including HLA-A, may influence susceptibility to human African trypanosomiasis (HAT), though studies have not found significant associations with APOL1 risk alleles [1, 2].

5.4 Autoimmune Disease Associations

HLA-A alleles are implicated in several autoimmune diseases:

• Behçet's disease: HLA-A*26:01 is the strongest genetic risk factor for ocular involvement in Japanese patients [<a href="#ref-1">1</a>].
• Vitiligo: HLA-A*02:01 is associated with generalized vitiligo, likely through presentation of melanocyte-derived antigens [<a href="#ref-3">3</a>].
• Multiple sclerosis: HLA-A*03:01 is associated with MS susceptibility in some populations [<a href="#ref-2">2</a>], while HLA-B*44 is protective [<a href="#ref-4">4</a>].
• Type 1 diabetes: HLA-A*02:01 is associated with increased risk, particularly in combination with HLA-DR/DQ risk haplotypes.

6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

6.1 Pharmacogenomic Associations

HLA-A alleles are established pharmacogenomic biomarkers for drug hypersensitivity reactions:

• **HLA-A*31:01**: Strongly associated with carbamazepine-induced SJS/TEN, DRESS, and maculopapular exanthema in East Asian and European populations. Clinical guidelines (CPIC, DPWG) recommend HLA-A*31:01 genotyping before carbamazepine initiation in at-risk populations.
• **HLA-A*32:01**: Associated with vancomycin-induced DRESS [<a href="#ref-3">3</a>]. Genotyping may be considered in patients requiring prolonged vancomycin therapy.
• **HLA-A*02:01**: Associated with abacavir hypersensitivity in some studies, though HLA-B*57:01 is the primary risk allele.

6.2 Therapeutic Targeting of HLA-A

HLA-A itself is not directly targeted by small-molecule inhibitors, but it is central to several immunotherapeutic strategies:

• Immune checkpoint inhibitors: Anti-PD-1 (pembrolizumab, nivolumab) and anti-PD-L1 (atezolizumab, durvalumab) antibodies rely on HLA-A-mediated tumor antigen presentation for efficacy. Tumors with HLA-A loss-of-function mutations are resistant to these agents.
• Adoptive T-cell therapy: TCR-engineered T cells targeting HLA-A-restricted tumor antigens are in clinical development. Examples include:
• NY-ESO-1 TCR-T cells: Target the HLA-A*02:01-restricted NY-ESO-1 peptide (SLLMWITQC) for the treatment of synovial sarcoma, melanoma, and multiple myeloma [<a href="#ref-5">5</a>].
• WT1 TCR-T cells: Target HLA-A*24:02-restricted WT1 peptides for acute myeloid leukemia and myelodysplastic syndromes [<a href="#ref-1">1</a>].
• Peptide vaccines: HLA-A-restricted epitopes are used in therapeutic cancer vaccines. Examples include:
• Melanoma antigens: MART-1/Melan-A (AAGIGILTV), gp100 (YLEPGPVTA), and tyrosinase (YMDGTMSQV) peptides restricted by HLA-A*02:01 [<a href="#ref-2">2</a>].
• WT1 peptide vaccine: Modified 9-mer WT1 peptides with enhanced HLA-A*24:02 binding affinity have been developed to improve CTL induction [<a href="#ref-1">1</a>].
• Monoclonal antibodies: Anti-HLA-A antibodies are used in research and diagnostic settings but are not approved for therapeutic use. The W6/32 antibody recognizes a monomorphic epitope on HLA class I molecules and is widely used for flow cytometry and immunohistochemistry [<a href="#ref-5">5</a>].

6.3 Investigational Approaches

• Bispecific T-cell engagers (BiTEs): Bispecific antibodies targeting HLA-A-restricted peptide–MHC complexes and CD3 are in preclinical development for cancer therapy.
• TCR-mimic antibodies: Antibodies that recognize specific peptide–HLA-A complexes, mimicking TCR specificity, are being developed for solid tumors.
• Gene editing: CRISPR/Cas9-mediated knockout of HLA-A in allogeneic cell therapies (e.g., CAR-T cells) is being explored to prevent graft rejection and GVHD.

7. Bioinformatic Resources & Database Accessions

Related Clinical & Scientific Guides

• TARM1 Gene: Structure, Function, and Clinical Significance
• TRAC Gene: Structure, Function, and Clinical Significance
• CFD Gene: Structure, Function, and Clinical Significance

References